$0.89
0.52% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Vaxart, Inc. Stock price

$0.89
+0.28 45.69% 1M
-0.31 26.23% 6M
+0.31 54.54% YTD
+0.09 10.65% 1Y
-7.82 89.84% 3Y
+0.19 27.04% 5Y
-24.74 96.55% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.00 0.52%
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Key metrics

Market capitalization $201.33m
Enterprise Value $161.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.62
P/S ratio (TTM) P/S ratio 14.45
P/B ratio (TTM) P/B ratio 2.52
Revenue growth (TTM) Revenue growth 577.76%
Revenue (TTM) Revenue $13.93m
EBIT (operating result TTM) EBIT $-75.05m
Free Cash Flow (TTM) Free Cash Flow $-62.42m
Cash position $62.59m
EPS (TTM) EPS $-0.46
P/E forward negative
P/S forward 6.42
EV/Sales forward 5.16
Short interest 6.00%
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

Buy
100%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
14 14
576% 576%
100%
- Direct Costs 4.60 4.60
15% 15%
33%
9.33 9.33
581% 581%
67%
- Selling and Administrative Expenses 14 14
23% 23%
97%
- Research and Development Expense 66 66
19% 19%
475%
-70 -70
30% 30%
-506%
- Depreciation and Amortization 4.60 4.60
15% 15%
33%
EBIT (Operating Income) EBIT -75 -75
28% 28%
-539%
Net Profit -76 -76
25% 25%
-543%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.
Neutral
Seeking Alpha
30 days ago
Vaxart, Inc. (NASDAQ:VXRT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - CFO Conference Call Participants Elaine Kim - Cantor Fitzgerald Operator Greetings and welcome to the Vaxart Business Update and Second Quarte...
Neutral
GlobeNewsWire
about one month ago
BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 125
Founded 2004
Website www.vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today